Information Provided By:
Fly News Breaks for July 5, 2017
NUVA
Jul 5, 2017 | 05:55 EDT
Piper Jaffray analyst Matt O'Brien views NuVasive's LessRay technology, which can reduce surgical radiation exposure by up to 90%, as an underappreciated growth driver for the company. The market size for LessRay is around $500M in the U.S. alone, a figure that increases as NuVasive adds more features to the system in the coming years, O'Brien tells investors in a research note. The analyst "conservatively" estimate the company will generate around $10M in sales from this technology next year. He encourages investors to start or build positions in NuVasive. O'Brien has an Overweight rating in the shares with a $90 price target.
News For NUVA From the Last 2 Days
There are no results for your query NUVA